Pazopanib News and Research

RSS
Pazopanib is an investigational, oral, once-daily angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit. VEGF and PDGF are growth factors critical to the development and growth of blood vessels – a process known as angiogenesis. Angiogenesis plays a pivotal role in the growth and spread of several tumor types, with VEGF and PDGF overexpression linked to multiple cancers including cancers of the liver, lung, breast, kidney, bladder, ovaries, and colon. By inhibiting VEGFR, PDGFR, and c-kit, pazopanib may stop or slow the rate of tumor growth and development. Pazopanib is currently being studied in a number of different tumor types; clinical trials are currently underway in RCC, breast cancer, ovarian cancer, soft tissue sarcoma, NSCLC, cervical cancer and other solid tumors. It is being evaluated as a monotherapy, in combination with targeted therapies and in combination with cytotoxic chemotherapy.
Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

No added benefit with pazopanib over ranibizumab for neovascular AMD

No added benefit with pazopanib over ranibizumab for neovascular AMD

Study: Cancer drug may help reduce bleeding in HHT patients

Study: Cancer drug may help reduce bleeding in HHT patients

18F-FGD-PET measures predict mRCC TKI response

18F-FGD-PET measures predict mRCC TKI response

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Patient with advanced bladder cancer shows complete response to everolimus and pazopanib drugs

Analysis on long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma

Analysis on long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

Aligned approach to advanced bladder cancer treatment very much needed, study says

Aligned approach to advanced bladder cancer treatment very much needed, study says

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Novel abnormalities in FGFR gene identified in a spectrum of cancers

Novel abnormalities in FGFR gene identified in a spectrum of cancers

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

Sunitinib does not cause lingering risks for cancer patients after their treatment ends

Sunitinib does not cause lingering risks for cancer patients after their treatment ends